Consistent with the established mechanism of action of the PD-L1 inhibitor atezolizumab, we confirm up-regulation of immune effector gene signatures in tumor tissues under the combination therapy, including signatures associated with CD8 + T cell effector functions and antigen processing machinery. The gene discussed is CD8A; the disease is neoplasm.